Herceptin | search
Click here to view Herceptin news from 60+ newspapers.
Bookmark or Share- How Herceptin is Thought to WorkHerceptin administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of Herceptin administration. Interrupt Herceptin infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve.
- herceptin - HER2+ Breast & Stomach Cancer Treatment OptionHerceptin HYLECTA: What it treats Adjuvant Breast Cancer. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes ...
- Herceptin Treatment ScheduleRead about the treatment schedule for Herceptin® (trastuzumab), a treatment for HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information. For US Healthcare Professionals
- Preparing for Treatment for HER2+ Early Breast Cancer - herceptinFind information about preparing for Herceptin® (trastuzumab) infusion treatment for HER2+ early breast cancer. See full safety & Boxed Warnings for more information.
- Herceptin® (trastuzumab) Dosing in HER2+ Adjuvant Breast CancerOne week following the last weekly dose of Herceptin, administer Herceptin at 6 mg/kg as an intravenous infusion over 30-90 minutes every three weeks As a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:
More
